CompaniesIdera Pharmaceuticals

Idera Pharmaceuticals

defunct

About

Defunct Company

Areas of Focus

Categories

Rebranded/RenamedBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (15)

Total Trials

15

As Lead Sponsor

13

As Collaborator

2

Total Enrollment

1,237

By Phase

PHASE2: 7PHASE1: 4PHASE3: 1PHASE1/PHASE2: 3

By Status

COMPLETED: 11TERMINATED: 2RECRUITING: 1ACTIVE_NOT_RECRUITING: 1

Clinical Trials Pipeline15 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

2032

Today

Hover over trial bars to see details

Recent Trials

NCT04126876Collaborator

A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma

PHASE2Recruiting

214 participants

Started: Jan 22, 2020 · Completed: Nov 1, 2031

NCT04196283Collaborator

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

PHASE1Completed

30 participants

Started: Jan 22, 2020 · Completed: Oct 27, 2022

NCT03865082Lead Sponsor

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

PHASE2Active, not recruiting

30 participants

Started: Oct 29, 2019 · Completed: Apr 30, 2022

NCT03445533Lead Sponsor

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

PHASE3Terminated

481 participants

Started: May 30, 2018 · Completed: Jun 1, 2021

NCT03052205Lead Sponsor

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

PHASE1Completed

54 participants

Started: Jun 9, 2017 · Completed: Oct 4, 2019

View all 15 trials →

Funding History (20)

8-K

Aug 16, 2023

DEF 14A

Jul 21, 2023

8-K

Jul 21, 2023

DEFA14A

Jul 11, 2023

8-K

Jul 11, 2023

8-K

May 30, 2023

8-K

May 4, 2023

8-K

Mar 30, 2023

8-K

Feb 6, 2023

8-K

Feb 3, 2023